When was Dogwood Therapeutics founded?

Dogwood Therapeutics was founded in 2020.

Where is Dogwood Therapeutics located?

Dogwood Therapeutics is headquartered in Alpharetta, United States.

Who is the current CEO of Dogwood Therapeutics?

Greg Duncan of Dogwood Therapeutics.

How many employees does Dogwood Therapeutics have?

As of Aug 31, 2026, the latest employee count at Dogwood Therapeutics is 9.

Where does Dogwood Therapeutics rank among its competitors?

Dogwood Therapeutics ranks 47th amongst 329 active competitors, of which 83 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Quince Therapeutics, which secured $187M in May, 2026.

Who are the top competitors of Dogwood Therapeutics?

Dogwood Therapeutics' top competitors include argenx, Vor Biopharma and Heron Therapeutics. Among them, Quince Therapeutics secured the most recent funding round in May, 2026.

Dogwood Therapeutics - 2026 Company Profile, Team & Competitors

Dogwood Therapeutics is a public company based in Alpharetta (United States), founded in 2020 by William Pridgen. It operates as a Developer of therapeutics for pain and fatigue. The company has 329 active competitors, including 83 funded and 92 that have exited. Its top competitors include companies like argenx, Vor Biopharma and Heron Therapeutics.

Company Details

Developer of therapeutics for pain and fatigue. It offers a lead product Halneuron which is a highly selective sodium channel blocker, for the treatment of moderate-to-severe chemotherapy induced neuropathic pain.

Website: www.dwtx.com/
Social
Email ID: *****@dwtx.com
Phone Number: +1 **********

Key Metrics

Founded Year

2020

Location

Alpharetta, United States

Stage

Public

Ranked

47^th among 329 active competitors

Employee Count

9 as on Aug 31, 2026

Similar Companies

Heron Therapeutics & 279 more

Exit Details

Public

View Dogwood Therapeutics' full profile

Dogwood Therapeutics is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Dogwood Therapeutics, Inc. CIN: 1818844 , United States, Active		-	-	-

Dogwood Therapeutics got listed on Dec 17, 2020.

Click here to take a look at Dogwood Therapeutics's IPO in detail

Dogwood Therapeutics has not raised any funding rounds yet.

The founders of Dogwood Therapeutics is William Pridgen. Greg Duncan is the CEO of Dogwood Therapeutics.

Here are the details of Dogwood Therapeutics' key team members:

William Pridgen: Founder of Dogwood Therapeutics.
Greg Duncan: CEO of Dogwood Therapeutics.
Contact Info: 1 email address

View details of Dogwood Therapeutics's Founder profiles and Board Members

Dogwood Therapeutics' employee count trend

Dogwood Therapeutics has 9 employees as of Aug 26. Here is Dogwood Therapeutics's employee count trend over the years:

Employee count trend for Dogwood Therapeutics

Uncover Dogwood Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Dogwood Therapeutics include argenx, Vor Biopharma and Heron Therapeutics. Here is the list of Top 10 competitors of Dogwood Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	argenx 2008, Ghent (Belgium), Public	Developer of antibody-based drugs to treat autoimmune diseases and cancer	$61.9M	Life Sciences Partners, Seventure Partners ... & 21 others	75/100
2nd	Vor Biopharma 2019, Cambridge (United States), Public	Developer of therapeutics to treat acute myeloid leukemia	$152M	NEXTBio, Mingxin Capital & 10 others	68/100
3rd	Heron Therapeutics 1983, Redwood City (United States), Public	Pharmaceutical company focused on acute care and oncology with innovative therapies	-	Deep Track Capital, Rubric Capital & 9 others	63/100
4th	Radius Health 2003, Boston (United States), Acquired	Biopharmaceutical company focused on bone health and related therapeutic areas	$213M	MPM BioImpact, Wellcome & 14 others	63/100
5th	Xenon Pharmaceuticals 2000, Burnaby (Canada), Public	Developer of small molecule drugs against rare channelopathies	$85.7M	Fidelity Investments, Invesco & 14 others	62/100
6th	Collegium Pharma 2002, Canton (United States), Public	Developer of therapeutics for chronic pain management	$103M	Longitude Capital, Skyline Ventures & 9 others	62/100
7th	Horizon Therapeutics 2008, Dublin (Ireland), Acquired	Developer of drugs for treating rare and autoimmune diseases	$61.8M	Atlas Venture, Avoro Capital & 4 others	61/100
8th	Quince Therapeutics 2012, San Francisco (United States), Public	Developer of therapeutics for orthopedic diseases	$108M	Pfizer Venture Investments, Balyasny Asset Management ... & 27 others	60/100
9th	Latigo Biotherapeutics 2019, Thousand Oaks (United States), Public	Developer of non-opioid pain medicines for central nervous system	$322M	Foresite Capital, Qatar Investment Authority ... & 11 others	60/100
10th	Foresee Pharmaceuticals 2011, Taipei (Taiwan), Public	Developer of injectables and NCEs for cancer and chronic diseases	$32.5M	CDIB Capital Group, Vivo Capital & 4 others	59/100
47th	Dogwood Therapeutics 2020, Alpharetta (United States), Public	Developer of therapeutics for pain and fatigue	-	-	47/100